Showing 5171-5180 of 6964 results for "".
- Midmark Gives Back: Trade-in Program Results in Nearly 1,000 Exam Tables Donated to World Visionhttps://practicaldermatology.com/news/midmark-gives-back-trade-in-program-results-in-nearly-1000-exam-tables-donated-to-world-vision/2461347/Midmark Corp.'s 2021 trade-in program collected 1,000 eligible exam tables. The tables were donated primarily to World Vision, where they are refurbished and delivered to clinics that provide health c
- Chicken or the Egg? Unravelling the Role of Demodex in Rosaceahttps://practicaldermatology.com/news/chicken-or-the-egg-unravelling-the-role-of-demodex-in-rosacea/2461346/Researchers have long observed that microscopic mites that live as scavengers on normal human skin tend to occur in greater numbers on the faces of rosacea patients. It was unknown, however, whether the higher density of these Demodex, was a cause or an effect of this widespread disease.
- Society for Pediatric Dermatology Issues Statement on Monkeypoxhttps://practicaldermatology.com/news/society-for-pediatric-dermatology-issues-statement-on-monkeypox/2461343/With the monkeypox outbreak recently being declared as a public health emergency, the
- Baby Dove Doubles Down Efforts to Close the Maternal Care Gap with #DearDoula and Greater Investment in Black Birth Equity Fundhttps://practicaldermatology.com/news/baby-dove-doubles-down-efforts-to-close-the-maternal-care-gap-with-deardoula-and-greater-investment-in-black-birth-equity-fund/2461342/Baby Dove is expanding the Black Birth Equity Fund, launching a new informative series called #DearDoula, and reinforcing existing strategic partnerships to help close the significant gap in care and health outcomes for Black mothers and their babies. "As a brand that encourages al
- FDA Approves BMS' Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-bms-sotyktu-for-plaque-psoriasis/2461341/The FDA has approved Bristol Myers Squibb Sotyktu (deucravacitinib), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Sotyktu is not recom
- Dermalogica Gives Back: Brand Launches Grant Program to Empower the Next Generation of Industry Proshttps://practicaldermatology.com/news/dermalogica-gives-back-brand-launches-grant-program-to-empower-the-next-generation-of-industry-pros/2461337/Dermalogica is offering a new grant program for non-profit organizations that help give greater access to skillset training in the United States. The grant program is now accepting applications and supports education, mentorship, and skills training for non-profits training therap
- DREAM Initiative from Allergan Aesthetics, SkinBetter Science Launches CARE Curriculumhttps://practicaldermatology.com/news/dream-initiative-from-allergan-skinbetter-science-launches-care-curriculum/2461334/The DREAM Initiative®, developed by Allergan Aesthetics and skinbetter science®, has supported the development of a racial equity curriculum for dermatology residency programs. The Curriculum f
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signali
- Paul Navarre Joins LEO Pharma’s Board of Directorshttps://practicaldermatology.com/news/paul-navarre-joins-leo-pharmas-board-of-directors/2461324/Paul Navarre is the newest member of LEO Pharma’s Board of Directors. Mr. Navarre currently serves as chairman of the Board of Directors at HTL (dermatology) and Arkopharma (Dietary Supplements), as Vice Chairman of Hallura (dermatology) and as Strategic Advisor to other companies